Today: 1 May 2026
Browse Category

NYSE:MRK 27 December 2025 - 9 January 2026

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck shares rose 0.4% to $111.41 Friday after a report said it is in talks to buy Revolution Medicines for $28–32 billion. Revolution shares jumped 16% in extended trading. Merck just completed a $221.50-per-share tender offer for Cidara Therapeutics and said the deal will raise 2026 R&D expense by $9 billion. Analysts warned U.S. vaccine policy changes could cut Merck revenue by $2 billion annually.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck shares rose 1.1% to $108.60 Tuesday, hitting a 52-week high of $110.16 amid investor focus on U.S. vaccine schedule changes and upcoming CEO remarks at the J.P. Morgan Healthcare Conference Jan. 12. The company’s Gardasil HPV vaccine faces uncertainty after the CDC shifted to a single-dose recommendation, while an FDA decision on Keytruda in ovarian cancer is expected Feb. 20.
6 January 2026
··
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck shares rose 1.2% to $106.45 Friday after Nasdaq set Jan. 6 as the expiration for its $9.2 billion cash tender offer for Cidara Therapeutics. Cidara shares will be halted after Jan. 6 and suspended Jan. 8 if the merger closes as planned. Merck’s move snapped a three-day losing streak, leaving the stock just below its 52-week high. About 10 million shares traded, below the 50-day average.
3 January 2026
···
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson closed Friday up 0.19% at $207.35 after declaring a $1.30-per-share quarterly dividend, payable March 10 to shareholders of record as of Feb. 24. The stock traded between $203.68 and $207.37 during the session. Investors await J&J’s Jan. 21 earnings call and next week’s U.S. labor data. The S&P 500 finished up 0.19%.
3 January 2026
·····
Merck (MRK) stock holds steady as Wall Street cools into year-end trade

Merck (MRK) stock holds steady as Wall Street cools into year-end trade

Merck shares edged up a penny to $106.79 in Monday afternoon trading, moving in a tight range on volume of about 4.1 million. The Health Care Select Sector SPDR ETF slipped 0.05% as health-care stocks held steady while major indexes fell. Investors are awaiting Fed minutes and monitoring year-end market signals. Merck’s next earnings report is set for February 3.
29 December 2025
Merck stock holds steady as year-end trading thins and Wall Street slips

Merck stock holds steady as year-end trading thins and Wall Street slips

Merck shares slipped 0.1% to $106.68 midday Monday, outperforming broader U.S. markets as the S&P 500 ETF fell 0.6% and the Nasdaq-100 tracker dropped 0.7%. Trading volumes remained thin ahead of Federal Reserve minutes due Tuesday. Investors await Merck’s Feb. 3 earnings call for 2026 guidance and pipeline updates. Pending U.S. home sales rose 3.3% in November, beating forecasts.
29 December 2025
··
1 2 3 4 5 6 7

Stock Market Today

  • Stock futures dip after mixed earnings from Microsoft and Meta; S&P 500 hits record high
    May 1, 2026, 6:24 AM EDT. Stocks surged Thursday with the S&P 500 closing above 7,200 for the first time, reaching an all-time high driven by strong earnings from Caterpillar and Alphabet. Caterpillar's nearly 10% jump and positive outlook suggest resilience despite lackluster U.S. economic growth in Q1. Alphabet's revenue beat and increased 2026 capital spending also buoyed markets. However, Meta and Microsoft shares declined 8.6% and 3.9%, respectively, due to rising capital expenditure concerns and disappointing user growth. Experts remain cautious about long-term tech valuations amid heavy investment in AI infrastructure. Still, April marked a strong month for major indices: the S&P 500 up 10.4%, Nasdaq 15.3%, and Dow 7.1%, signaling investor optimism despite underlying uncertainties.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 6:31 AM EDT Stock futures dip after mixed earnings from Microsoft and Meta; S&P 500 hits record high May 1, 2026, 6:24 AM EDT. Stocks surged Thursday with the S&P 500 closing above 7,200 for the first time, reaching an all-time high driven by strong earnings from Caterpillar and Alphabet. Caterpillar's nearly 10% jump and positive outlook suggest resilience despite lackluster U.S. economic growth in Q1. Alphabet's revenue beat and increased 2026 capital spending also buoyed markets. However, Meta and Microsoft shares declined 8.6% and 3.9%, respectively, due
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Go toTop